Orally bioavailable small-molecule Interdictors that inhibit ribosome-mediated protein synthesis in a context-dependent manner by engaging the nascent polypeptide, enabling targeting of historically undruggable proteins. Develops therapeutics focused on oncology (including MYC-dependent cancers) and neurodegenerative diseases.